Abstract
The transplantation of mobilised peripheral blood stem cells is associated with more rapid engraftment than marrow transplantation. We have previously reported that G-IVE (G-CSF, ifosphamide, VP-16, epirubicin) improves the yield of CD34+ cells mobilised in patients with lymphoproliferative disorders compared with cyclophosphamide 3 g/m2 and G-CSF (G/CYCLO). In this study we have extended these observations to a larger series of patients including different lymphoma subtypes. Ninety-seven patients undergoing stem cell mobilisation were studied. Forty-two patients with lymphoproliferative disorders received G-IVE for mobilisation and 55 patients G/CYCLO. The median number of mobilised CD34+cells per leucapheresis was significantly higher for those patients receiving G-IVE: 5.82 × 106/kg (0.19–36) compared with 1.2 × 106/kg (0.04–17), P < 0.001 which resulted in a significantly reduced number of leucapheresis procedures performed in the g-ive group. when patients were analysed dependent on underlying disease g-ive mobilised significantly more cd34+cells per leucapheresis for all lymphoma types reaching 8.41 × 106/kg (0.2–32) compared to 1.32 × 106/kg (0.06–17) for patients with high-grade NHL mobilised with G-IVE and C-GCSF respectively (P = 0.012). For patients with low-grade NHL 3.12 × 106/kg (0.10–24.39) compared to 1.08 × 106/kg (0.04–9.74) were collected (P = 0.04) and for patients with Hodgkin’s disease 3.02 × 106/kg (1.48–36) and 1.04 × 106/kg (0.1–12.3) (P = 0.001). Mobilisation with G-IVE resulted in the achievement of clinically significant CD34+ cell thresholds in a significantly higher proportion of patients compared to cyclophosphamide and G-CSF reaching >2.5 × 106/kg CD34+ cells in 88% vs 62% (P = 0.004), >5 x 106/kg in 67% vs18% (P = 0.001) and >10 × 106/kg in 31% vs 14.5% (P = 0.05). Furthermore, an analysis of engraftment demonstrated that there was a significant reduction in the time to achieve platelet counts of >20 and >50 × 109/l in patients receiving each incremental dose of CD34+ cells. We conclude that G-IVE mobilises significantly more CD34+cells than G/CYCLO in patients with lymphoproliferative disorders. This effect is consistent in patients with high-grade NHL, low-grade NHL and HD and results in fewer failed stem collections and increased CD34+ cells available for transplantation which results in significantly accelerated platelet engraftment post transplant.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McQuaker, I., Haynes, A., Stainer, C. et al. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin’s lymphomas and Hodgkin’s disease. Bone Marrow Transplant 24, 715–722 (1999). https://doi.org/10.1038/sj.bmt.1701985
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701985
Keywords
This article is cited by
-
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
Leukemia (2019)
-
Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF
Bone Marrow Transplantation (2009)
-
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients
Bone Marrow Transplantation (2007)
-
Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment
Annals of Hematology (2005)
-
Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?
Bone Marrow Transplantation (2003)